Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

AstraZeneca pushes back timeline for MYSTIC phase III lung cancer clinical trial

Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first
AstraZeneca pushes back timeline for MYSTIC phase III lung cancer clinical trial
The open-label efficacy assessment was designed to test the combination therapy against the current gold standard chemotherapy for patients with a form of locally-advanced or metastatic non-small cell lung cancer

AstraZeneca PLC (LON:AZN) said the timeline for its closely-followed MYSTIC clinical trial, treating patients with late-stage lung cancer has been pushed back.

Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first.

MYSTIC deployed Imfinzi, developed by AZ’s US biotechnology arm MedImmune, in combination with tremelimumab, an antibody treatment also created by the company’s American research arm.

The open-label efficacy assessment was designed to test the combination therapy against the current gold standard chemotherapy for patients with a form of locally-advanced or metastatic non-small cell lung cancer.

The trial is being conducted in 167 centres across 17 countries, including the US, Canada, Europe, and parts of Asia.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use